EpSSG Association

The European Paediatric Soft tissue sarcoma Study Group (EpSSG) is an international organisation for professionals devoted to the care and treatment of children and young people with cancers known as soft tissue sarcoma (STS). This includes the most common STS, rhabdomyosarcoma (RMS), and a wide range of other cancers known collectively, as Non Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS).
The legal entity for EpSSG activities is the EpSSG Association. This exists to promote and manage clinical trials, encourage and facilitate clinical and basic science research, foster optimal standards of care, organise educational meetings for its members and other professionals, and advocate for patients with STS.
It collaborates with other similar groups in Europe, North America and elsewhere.
EpSSG has its administrative and legal home in Padua, Italy. It is managed by an elected board, and its membership is open, by application, to professionals who have an interest in the research or treatment of these diseases when they occur in children, teenagers and young adults.

News

23 May 2019

EpSSG Spring Prague MEETING 2019

EPSSG Spring Meeting Prague 2019

Prague May 23-24 2019

Location: Prague, Czech Republic

Read more
07 February 2019

NEW EpSSG PAPER first of 2019!!

Indeterminate pulmonary nodules at diagnosis in rhabdomyosarcoma; Are they clinically significant? A report from the European paediatric Soft tissue sarcoma Study Group

January 31, 2019 the EpSSG study entitled 'Indeterminate pulmonary nodules at diagnosis in rhabdomyosarcoma; Are they clinically significant? A report from the European paediatric Soft tissue sarcoma Study Group' was published online in Journal of Clinical Oncology. In this study we assessed the clinical value of small lung nodules, not fulfilling the criteria for pulmonary metastases. This was an EpSSG radiology study, conducted in 15 larger centers in the United Kingdom, France, Italy and the Netherlands. We showed that small lung nodules are a frequently encountered diagnostic problem, occurring in over 20% of the patients with otherwise localized rhabdomyosarcoma. More importantly, this study showed that the presence of small lung nodules did not impact survival in patients with otherwise localized rhabdomyosarcoma, treated according to the RMS2005 protocol for localized disease. This study proves that patients with small lung nodules do not require additional chest radiotherapy and/or intensified chemotherapy. These results will be used in the upcoming EpSSG Frontline and Relapsed-RMS study.

Read more